Report on the 2017 Society for Neuro-Oncology Annual Meeting

Manmeet S Ahluwalia MD (Dr. Ahluwalia of Cleveland Clinic received research funding from Monteris Medical, Abbvie, BMS, Astrazeneca, and Novacure, and Novartis and honorariums for his service as a consultant from Monteris Medical, Abbvie, BMS, AstraZeneca, and CBT Pharmaceuticals.)
Sean Sachdev MD (Dr. Sachdev of Northwestern University, Feinberg School of Medicine has no relevant financial relationships to disclose.)
Rimas V Lukas MD (Dr. Lukas of Northwestern University Feinberg School of Medicine received honorariums from AstraZeneca as an advisory board member and AbbVie as a guest speaker and advisory board member.)
Originally released December 21, 2017; expires December 21, 2020

Overview

The 22nd annual meeting of the Society for Neuro-Oncology (SNO) was held in San Francisco, California from November 16 to November 19th, 2017. The Scientific Program chairs were Manish Aghi, Frank Furnari, and Vinay Puduvalli. The Education Program chairs were Khalid Shah, Albert Kim, Susan Bell, and Robert Cavaliere. The official meeting was preceded by the Neuro-Oncology Review Course chaired by Maciej Mrugala and the SNO-Society for CNS Interstitial Delivery of Therapeutics (SCIDOT) meeting chaired by Michael Vogelbaum and Manish Aghi. There were over 2,500 attendees for the main meeting. Over 1,200 abstracts were submitted, and there were almost 250 oral presentations. Attendees came from a range of disciplines including medical neuro-oncology, surgical neuro-oncology, radiation oncology, neuropathology, neuroradiology, and others. There were physicians, advanced practice providers, nurses, basic scientists, industry representatives, and patient advocates in attendance in concordance with the multidisciplinary nature of the field. We attempt to provide a succinct overview of key studies presented at the meeting covering both primary and metastatic CNS tumors. This meeting report is by no means comprehensive, and much of the important work is unable to be highlighted. We would refer readers to the abstracts found in volume 19, supplement 6 of Neuro-Oncology (https://academic.oup.com/neuro-oncology/issue/19/suppl_6) for further reading. An overview of the trials underlying the current standard of care for infiltrating gliomas can be found in a recently published review (Lukas and Mrugala 2017). The evolving management of brain metastases has also been recently reviewed (Venur and Ahluwalia 2017).

The content you are trying to view is available only to logged in, current MedLink Neurology subscribers.

If you are a subscriber, please log in.

If you are a former subscriber or have registered before, please log in first and then click select a Service Plan or contact Subscriber Services. Site license users, click the Site License Acces link on the Homepage at an authorized computer.

If you have never registered before, click Learn More about MedLink Neurology  or view available Service Plans.